Data from two serial studies comparing the MRI activity of two groups of 11 patients, one with early relapsing-remitting (mean disease duration 3 5 years), the other benign (mean disease duration 22 years) multiple sclerosis are presented. Those with benign disease developed fewer new or enlarging lesions, and such lesions that occurred had a lower incidence of gadolinium enhancement, a marker of inflammation. These results, when considered in conjunction with other published studies, suggest that both the frequency of new lesions and the amount of inflammation within them influence the development of disability in multiple sclerosis. design, and now present the combined results of the two studies, with particular emphasis on the insights they provide into the mechanisms of disability in multiple sclerosis.
The benign form of multiple sclerosis is defined as the presence of minimal disability at least 10 years after the onset of symptoms'; its incidence has been cited as between 15 and 40%2-5 depending on the criteria used. The pathophysiological mechanisms that lead to a benign course in some patients, and the accumulation of severe disability in others, are poorly understood. It Longitudinal MRI studies, which document the evolution of lesions over time, pro- vide additional information about disease activity. In a previous study we reported two small groups of relapsing-remitting patients with multiple sclerosis with different disease durations-early relapsing-remitting and benign multiple sclerosis-who underwent monthly brain MRI for six months.9 During this period, the benign group developed fewer new lesions, and a smaller proportion of the new lesions displayed gadolinium enhancement. Because of the small numbers of patients, this was not a definitive study. We therefore enlarged the earlier cohorts of patients with early relapsing-remitting and benign multiple sclerosis with the same study design, and now present the combined results of the two studies, with particular emphasis on the insights they provide into the mechanisms of disability in multiple sclerosis.
Patients and methods Twelve patients with clinically definite multiple sclerosis10 were selected from the patient population attending the National Hospitals for Neurology and Neurosurgery. All had oligoclonal bands in the CSF and all gave informed written consent to enter the study. Selection was based on willingness to participate and on disability state (expanded disability status scale (EDSS) < 3-0). Six patients had an early relapsing-remitting course defined as a disease duration of less than five years, six had a benign course defined as disease duration of greater than 10 years.
Patients underwent a full neurological examination at the onset of the study and MRI of the brain with gadolinium-DTPA enhancement. They were followed up with gadolinium enhanced MRI at monthly intervals for six months. At each visit they were questioned about new or recurring symptoms and were re-examined.
MRI PROTOCOL
Brain MR scans were obtained on a Signa 1 5T superconducting system (GE Milwaukee). T2 weighted and proton density weighted images were acquired with 34 lesions (p = 0 03). There was a significant difference in the number of new or enlarging lesions per patient per relapse between the two groups (6-25 in the early relapsingremitting group v 2-25 in the benign group, p < 0 03), in the number of new or enlarging lesions per patient (6-8 in the early relapsingremitting group v 19 in the benign group, p < 0 03), and in the proportion of those that displayed enhancement (80% in the early relapsing-remitting group v 38% in the benign group, p < 0-0001). There was no relation between the age of the patient and the frequency of active lesions on MRI (p > 0-1).
Discussion
The present study confirms our earlier findings. Combining the results of the two studies gives a cohort of 11 patients each with early relapsing-remitting and benign multiple sclerosis, and the results show that active lesions appear about one third as often in those with benign multiple sclerosis. Furthermore, new or enlarging lesions showed gadolinium-DTPA enhancement significantly less often in benign multiple sclerosis. As gadolinium enhancement is a marker of blood-brain barrier breakdown, which in multiple sclerosis correlates with the presence of inflammation," the decreased frequency of enhancement suggests a less severe or shorter inflammatory phase in the development of new lesions in benign nmultiple sclerosis.
An important question, not answered by the present study, is whether the differences in disease activity are a consequence of differences in the duration of the disease rather than in its severity. Clinical relapses become less frequent with increasing disease duration,' so it is plausible that the number of active MRI lesions will also diminish. This question could be considered by studying a group of disabled relapsing-remitting or secondary progressive patients matched with the benign group for disease duration (patients with primary progressive multiple sclerosis and without superimposed relapses should not be included as they have a much smaller rate of MRI activity than secondary progressive patients m'atched for disease duration and disability).'2 A second issue is the possible effect of age on MRI activity; although no significant relation was found in this study, a possible reduction in MRI activity with advancing age cannot be excluded.
Although data are not available for disabled relapsing-remitting or secondary progressive patients with the same disease duration as our benign group, two studies of cohorts with a shorter disease duration suggest that the amount of MRI activity will be predictive of the long term clinical course. Firstly,'2 a group of 12 disabled patients with secondary progressive multiple sclerosis, with a mean disease duration (7-8 years) intermediate between the present early relapsing-remitting and benign groups, displayed an amount of MRI activity (mean 18-2 lesions per patient per year) and enhancement (87% of lesions) similar to that seen in the early relapsingremitting group and much in excess of that seen in the benign group.
Secondly, a recent five year follow up study of patients first scanned at presentation with a single episode compatible with demyelination (for example, optic neuritis), showed a strong correlation between the number of brain MRI lesions at presentation and the number of new lesions as well as the degree of clinical disability at follow up.13 Usually patients without disability had developed few new lesions during the preceding five years, and it is likely that many of these will go on to have benign disease, as it has been shown that the absence of appreciable disability after five years of clinical symptoms is associated with a high probability of remaining minimally disabled over the next [10] [11] [12] [13] [14] [15] 
